Nevertheless, this data clearly support the concept that combining MEKi with immunotherapy enhances IFNγ production, which has the potential to significantly enhance MHC-I expression and, consequently, tumor cell immunogenicity. The gene discussed is IFNG; the disease is neoplasm.